Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
820.00    -11.00 (-1.32%)
Bid:
816.00
Ask:
822.00
Spread: 6.00 (0.735%)
Market Cap: £774.61m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AUM Update

11 Oct 2018 07:00

RNS Number : 6489D
Polar Capital Holdings PLC
11 October 2018
 

11 October 2018 Polar Capital Holdings plc

AUM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the specialist asset management group, today provides its regular quarterly update of its unaudited statement of its Assets under Management ("AUM").

 

 

Group AUM (unaudited)

 

Polar Capital reports that as at 30 September 2018 its AUM were £14.7bn compared to £12.0bn at the end of March 2018.

 

AUM movement in six months to 30 September 2018

Long only

funds

Alternative funds

Total

AUM at

1 April 2018

£10,812m

£1,168m

£11,980m

Net subscriptions

/ (redemptions)

£739m

£193m

£932m

Market movement

and performance

£1,668m

£133m

£1,801m

Total AUM at

30 September 2018

£13,219m

£1,494m

£14,713m

 

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fee profits due to the Group (after the deduction of staff interests) as a product of accrued performance fees in funds managed by the Group three months before the strike point of such performance fee receipts. The majority of the Group's performance fees crystallise in the second half of the financial year.

 

Performance fees

net of staff allocations

Six months to

30 Sept 17

Year to

31 Mar 18

(year-end)

Six months to

30 Sept 18

Received

£0.0m

£15.3m

£5.5m

Accrued but not yet earned in funds with year ends on or before the financial year end

£9.6m

n/a

£27.0m*

Total net performance fee profits

£9.6m

£15.3m

£32.5m*

 

*the figures benefit from £4.6m of net performance fee distributions that will be deferred into future accounting periods that IFRS do not allow to be deducted from this year's receipts.

 

 

Comment

 

The Group has had another satisfactory quarter in terms of both performance and flows.

 

As is usual at the time of releasing this update, three months before the crystallisation of performance fees, we disclose the profits that could be due to Polar as a function of the amount of accrued performance fees in our funds as at the end of September. There is no certainty that the fees will be sustained over the next quarter, as performance fee receipts are extremely volatile, but nevertheless the quantum of potential net performance fee receipts is a marked improvement on the position of 2017, which itself was a record year in terms of such performance fee profitability.

 

It is also reassuring to report another quarter of positive net inflows with close to £240m received in the quarter following our first quarter of over £690m of net inflows. The flows this quarter were seen across a number of strategies including: our Technology, Healthcare, Insurance, Convertibles and UK Value strategies. In addition, we have successfully launched our EM Stars, China Stars and China Mercury funds.

 

 

For further information please contact:

 

Polar Capital

Gavin Rochussen (Chief Executive)

John Mansell (COO)

+44 (0)20 7227 2700

 

Canaccord Genuity - Nomad and Joint Broker

Simon Bridges (QE)

David Tyrrell

 

+44 (0)20 7523 8000

 

 

Peel Hunt - Joint Broker

Guy Wiehahn

 

+44 (0)20 7418 8893

 

Camarco

Ed Gascoigne-Pees

 

 

+44 (0)20 3757 4984

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEASEEFADPFFF
Date   Source Headline
4th Feb 20199:43 amRNSBlock listing Interim Review
1st Feb 201911:41 amRNSTotal Voting Rights
29th Jan 20194:41 pmRNSSecond Price Monitoring Extn
29th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20195:45 pmRNSIssue of Equity
28th Jan 20195:30 pmRNSDirector/PDMR Shareholding
10th Jan 201910:19 amRNSDirector/PDMR Shareholding
10th Jan 20197:00 amRNSAUM Update
2nd Jan 20199:49 amRNSTotal Voting Rights
12th Dec 20184:00 pmRNSIssue of Equity
27th Nov 20184:40 pmRNSSecond Price Monitoring Extn
27th Nov 20184:35 pmRNSPrice Monitoring Extension
26th Nov 20187:00 amRNSUnaudited Interim Results
22nd Nov 20185:00 pmRNSDirectorate Change
5th Nov 20187:01 amRNSNotice of Results
5th Nov 20187:00 amRNSChange of Nominated Adviser and Broker
1st Nov 20187:00 amRNSTotal Voting Rights
25th Oct 20185:26 pmRNSIssue of Equity
24th Oct 20184:52 pmRNSDirector/PDMR Shareholding
17th Oct 20185:49 pmRNSIssue of Equity
15th Oct 201812:38 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
12th Oct 20182:52 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
11th Oct 20184:42 pmRNSIssue of Equity
11th Oct 20187:01 amRNSCrystallisation of business unit & issue of shares
11th Oct 20187:00 amRNSAUM Update
3rd Oct 201810:24 amRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
19th Sep 201811:52 amRNSForm 8.3 - Jardine Lloyd Thompson Group
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
17th Aug 20189:27 amRNSDirectorate Change
6th Aug 20187:00 amRNSBlock listing Interim Review
1st Aug 20187:00 amRNSTotal Voting Rights
31st Jul 20185:57 pmRNSIssue of Equity
31st Jul 201811:29 amRNSDirector/PDMR Shareholding
25th Jul 20183:38 pmRNSDirectorate Change
25th Jul 20183:26 pmRNSResult of AGM
19th Jul 201811:13 amRNSForm 8.3 - Consort Medical Plc
18th Jul 20184:21 pmRNSDirector/PDMR Shareholding
18th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
17th Jul 201810:58 amRNSForm 8.3 - Consort Medical Plc
16th Jul 20183:44 pmRNSDirector/PDMR Shareholding
12th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
12th Jul 20187:00 amRNSAuM Update
11th Jul 201811:06 amRNSForm 8.3 - Consort Medical Plc
3rd Jul 20186:27 pmRNSHolding(s) in Company
3rd Jul 20186:20 pmRNSIssue of Equity
3rd Jul 201812:07 pmRNSForm 8.3 - Consort Medical Plc
2nd Jul 201810:23 amRNSTotal Voting Rights
29th Jun 20187:00 amRNSBlock Listing Application
28th Jun 20185:55 pmRNSAnnual Financial Report
25th Jun 20187:00 amRNSGroup Audited Results for year ended 31 March 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.